Abdominal Aortic Aneurysm (AAA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Abdominal Aortic Aneurysm (AAA) Market Outlook

Thelansis’s “Abdominal Aortic Aneurysm (AAA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Abdominal Aortic Aneurysm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Abdominal Aortic Aneurysm (AAA) Overview

An Abdominal aortic aneurysm (AAA) is characterized by the enlargement of the lower segment of the aorta, the body's primary blood supply vessel, which extends from the heart through the chest and abdomen. Several factors contribute to the formation of AAA, including inflammation weakening the aortic artery wall, advanced age (50+ for men, 60+ for women), a history of atherosclerosis, high blood pressure, elevated cholesterol, heart or peripheral vascular disease, and tobacco use. Those at the highest risk are men older than 60, smokers, Caucasians, and individuals with a first-generation relative who has had an AAA. Additional potential factors associated with AAA development include tears in the arterial wall, infections, and congenital connective tissue disorders. The diagnosis of an abdominal aortic aneurysm typically involves the use of ultrasound. However, a CT scan is required to determine its precise location, size, and impact on surrounding blood vessels, especially in symptomatic patients. The differential diagnosis for AAA includes Mesenteric ischemia, Peptic ulcer disease, Diverticulitis, Pyelonephritis, and Myocardial infarction. Treatment is recommended when the aneurysm diameter reaches 5 to 5.5 cm, shows rapid enlargement of more than 0.5 cm over six months, or becomes symptomatic. Open surgical repair via transabdominal or retroperitoneal approach has been the gold standard. The prognosis for AAA is grim, with an approximately 80% risk of death following a rupture. Most patients do not survive long enough to reach the hospital, and even with surgical intervention, the success rate for repairing a ruptured aneurysm is only 50%.

• It is important to note that each year in the USA, 200,000 people are diagnosed with an abdominal aortic aneurysm (AAA).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: